Cargando…

A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer’s disease

OBJECTIVE: Amyloid 1-42 (Aβ42) and tau in cerebrospinal fluid are currently used as markers for diagnosis of Alzheimer’s disease. Conflicting reports exist regarding their plasma levels in Alzheimer’s disease patients. A meta-analysis was performed to statistically validate the use of plasma Aβ42 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shanthi, Keerthanaa Balasubramanian, Krishnan, Sreeram, Rani, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679337/ https://www.ncbi.nlm.nih.gov/pubmed/26770797 http://dx.doi.org/10.1177/2050312115598250

Ejemplares similares

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta‐analyses
por: Alhajraf, Falah, et al.
Publicado: (2019)

Study on Analysis of Peripheral Biomarkers for Alzheimer’s Disease Diagnosis
por: Rani, Palaniswamy, et al.
Publicado: (2017)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β ((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop
por: Teunissen, Charlotte E., et al.
Publicado: (2010)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
por: Lee, Jinny Claire, et al.
Publicado: (2019)

Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease
por: Cheng, Yuan, et al.
Publicado: (2022)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2022)

Cerebrospinal Fluid β-Amyloid(1–42) Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis
por: Mo, Jin-A, et al.
Publicado: (2015)

Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer’s disease dementia in Chinese individuals
por: Sun, Qingling, et al.
Publicado: (2022)

Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy
por: de Kort, Anna M., et al.
Publicado: (2023)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
por: Wilczyńska, Karolina, et al.
Publicado: (2020)

Predicting amyloid PET and tau PET stages with plasma biomarkers
por: Jack, Clifford R, et al.
Publicado: (2023)

Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis
por: Ding, Xulong, et al.
Publicado: (2021)

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2021)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease
por: Fan, Dong-Yu, et al.
Publicado: (2021)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
por: Liu, Huei-Chun, et al.
Publicado: (2020)

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
por: Lue, Lih-Fen, et al.
Publicado: (2017)

Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease
por: Pascoal, Tharick, et al.
Publicado: (2023)

Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer’s Disease
por: Sharma, Abhinav, et al.
Publicado: (2023)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
por: Lue, Lih-Fen, et al.
Publicado: (2017)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease
por: Kwak, Sang Su, et al.
Publicado: (2020)

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
por: Kametani, Fuyuki, et al.
Publicado: (2018)

The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
por: Ashford, J. Wesson
Publicado: (2019)

Paper-Based Detection Device for Alzheimer’s Disease—Detecting β-amyloid Peptides (1–42) in Human Plasma
por: Sung, Wei-Hsuan, et al.
Publicado: (2020)

Preservation of Biomarkers Associated with Alzheimer’s Disease (Amyloid Peptides 1-38, 1-40, 1-42, Tau Protein, Beclin 1) in the Blood of Neonates after Perinatal Asphyxia
por: Tarkowska, Agata, et al.
Publicado: (2023)

New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
por: Park, Sun Ah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bg45tdpmhutnh1loc497cmuhjd